{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:28:40Z","timestamp":1787758120232,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>As a continuing demand for booster shots against SARS-CoV-2, ocular adverse events following the coronavirus disease-2019 (COVID-19) vaccines can cause significant visual impairment, and they warrant a high awareness and detailed documentation of possible ocular inflammatory manifestations. We present a case series of 11 patients presenting with ocular manifestations relevant to vaccine-associated autoimmune response within 6 weeks after the vaccination of the Oxford\u2013AstraZeneca, the Moderna, and Pfizer-BioNTech vaccines at the main tertiary referral center in the most populated and most vaccinated city in Taiwan. Their diagnosis included five acute anterior uveitis, two multiple evanescent white dot syndrome, one probable Vogt\u2013Koyanagi\u2013Harada disease, one anterior scleritis, one relapsed idiopathic panuveitis, and one autoantibody-related central retinal artery occlusion. This report presented a broad spectrum of the ocular inflammatory events following the vaccination of COVID-19. Early recognition of the clinical manifestations mentioned herein with prompt management is crucial in recovering the patients' vision.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2211-5056.353129","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T06:31:41Z","timestamp":1659335501000},"page":"465-471","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Ocular inflammatory manifestations following COVID-19 vaccinations in Taiwan"],"prefix":"10.4103","volume":"12","author":[{"given":"Ling-Uei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Lun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ray","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20240830","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R2-13-20240830","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R3-13-20240830","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/09273948.2020.1811352","article-title":"Clinical and epidemiological profiles of retinal vasculitis in Northern Taiwan","volume":"30","author":"Wang","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R4-13-20240830","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1080\/09273948.2016.1189577","article-title":"Patterns and etiologies of uveitis at a tertiary referral center in Taiwan","volume":"25","author":"Chen","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R5-13-20240830","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.2147\/OPTH.S224192","article-title":"Hyperbaric oxygen therapy for central retinal artery occlusion: Patient selection and perspectives","volume":"15","author":"Celebi","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R6-13-20240830","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"key":"R7-13-20240830","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R9-13-20240830","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-13-20240830","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3390\/vaccines9121404","article-title":"Ocular manifestations after receiving COVID-19 vaccine: A systematic review","volume":"9","author":"Lee","year":"2021","journal-title":"Vaccines (Basel"},{"key":"R11-13-20240830","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1097\/IAE.0000000000003277","article-title":"Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: A possible association","volume":"41","author":"Rabinovitch","year":"2021","journal-title":"Retina"},{"key":"R12-13-20240830","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40942-021-00319-3","article-title":"Vogt-Koyanagi-Harada syndrome following COVID-19 and ChAdO\u00d71 nCoV-19 (AZD1222) vaccine","volume":"7","author":"Saraceno","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R13-13-20240830","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-021-00251-5","article-title":"Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination","volume":"11","author":"Papasavvas","year":"2021","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R14-13-20240830","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/09273948.2021.1974492","article-title":"Vogt-Koyanagi-Harada disease associated with COVID-19 mRNA vaccine","volume":"29","author":"Koong","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R16-13-20240830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10792-006-9020-y","article-title":"Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease","volume":"27","author":"Sugita","year":"2007","journal-title":"Int Ophthalmol"},{"key":"R17-13-20240830","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/09273948.2019.1661498","article-title":"Vogt-Koyanagi-Harada-like disease following yellow fever vaccination","volume":"29","author":"Campos","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R18-13-20240830","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s40064-016-2223-4","article-title":"Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis","volume":"5","author":"Dogan","year":"2016","journal-title":"Springerplus"},{"key":"R19-13-20240830","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/09273948.2018.1483520","article-title":"Vogt-Koyanagi-Harada disease associated with hepatitis B vaccination","volume":"27","author":"Sood","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R20-13-20240830","doi-asserted-by":"crossref","first-page":"101516","DOI":"10.1016\/j.ajoc.2022.101516","article-title":"Vogt-Koyanagi-Harada disease following influenza vaccination","volume":"26","author":"Murtaza","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R21-13-20240830","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/0301-4738.178141","article-title":"Vogt-Koyanagi-Harada syndrome following influenza vaccination","volume":"64","author":"Kim","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R22-13-20240830","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamaophthalmol.2021.3477","article-title":"Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi","volume":"139","author":"Pichi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R23-13-20240830","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1007\/s10792-021-01971-2","article-title":"Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine","volume":"41","author":"Bialasiewicz","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R24-13-20240830","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/vaccines9111349","article-title":"Retinal vascular events after mRNA and adenoviral-vectored COVID-19 vaccines \u2013 A case series","volume":"9","author":"Girbardt","year":"2021","journal-title":"Vaccines (Basel"},{"key":"R25-13-20240830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1067\/mlc.2001.115525","article-title":"Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia\/thrombosis","volume":"138","author":"Visentin","year":"2001","journal-title":"J Lab Clin Med"},{"key":"R26-13-20240830","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/vaccines9060559","article-title":"Thrombotic thrombocytopenia after COVID-19 vaccination: In search of the underlying mechanism","volume":"9","author":"Rzymski","year":"2021","journal-title":"Vaccines (Basel"},{"key":"R27-13-20240830","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood.2021014684","article-title":"Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis","volume":"139","author":"Craven","year":"2022","journal-title":"Blood"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.353129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:07:00Z","timestamp":1787756820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.353129"}},"subtitle":["A case series"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/2211-5056.353129","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}